ARTIVION INC (AORT)
US2289031005 - Common Stock
Artivion Announces Release Date and Teleconference Call Details for First Quarter 2024 Financial Results
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that first quarter 2024...
Artivion to Participate in the 23rd Annual Needham Virtual Healthcare Conference
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate...
Artivion to Participate in the Oppenheimer 34th Annual Healthcare MedTech & Services Conference
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate...
Artivion files automatic mixed securities shelf (NYSE:AORT)
Artivion (AORT) files a prospectus for mixed shelf offering.
Artivion Reports Fourth Quarter and Full Year 2023 Financial Results
Fourth Quarter and Recent Business Highlights: Achieved revenue of $93.7 million in the fourth quarter of 2023 versus $79.4 million in the fourth quarter of...
Artivion Announces Release Date and Teleconference Call Details for Fourth Quarter and Full Year 2023 Financial Results
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that fourth quarter and...
Artivion Announces Presentation of Late-Breaking Data from AMDS PERSEVERE Trial at the 60th Society of Thoracic Surgery Annual Meeting
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the presentation of...
Artivion Obtains $350 Million in Senior Secured Credit Facilities
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced the closing of a...
Artivion Appoints Lance A. Berry as Executive Vice President, Chief Financial Officer; Announces Retirement of D. Ashley Lee, Chief Financial Officer
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease today announced the appointment of Lance...
Artivion (AORT) Shares Cross Above 200 DMA
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start Tuesday trading with a breakdown of the biggest pre-market stock movers worth keeping an eye on this morning!
Artivion Announces Completion of Enrollment in PERSEVERE Trial
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it has completed...
Artivion to Participate in Upcoming Investor Conferences
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate...
Artivion Reports Third Quarter 2023 Financial Results
Third Quarter and Recent Business Highlights: Achieved revenue of $87.9 million in the third quarter of 2023 versus $76.8 million in the third quarter of 2022,...
Artivion Announces Release Date and Teleconference Call Details for Third Quarter 2023 Financial Results
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that third quarter 2023...
RSI Alert: Artivion (AORT) Now Oversold
Artivion Announces Presentation of Real World Data from Post Market Study of On-X® Aortic Heart Valve Replacement Patients Treated with Low Dose Warfarin
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced data from its On-X...
Artivion Announces Presentation of Late-Breaking Interim Data from AMDS PERSEVERE Trial at the 37th European Association for Cardio-Thoracic Surgery Annual Meeting
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today presented interim results from the...
Artivion (AORT) Shares Cross Below 200 DMA
Artivion to Present at the Deutsche Bank 31st Annual Leveraged Finance Conference
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present at...
Artivion to Present at the Gilmartin Group Emerging Growth Company Showcase
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will present...
Artivion to Participate in Upcoming Investor Conferences
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that it will participate...
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2023 Financial Results
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, announced today that second quarter 2023...
Artivion wins FDA nod for Baxter-partnered clotting product
Artivion (AORT) announced Tuesday the FDA clearance for its PERCLOT Absorbable Hemostatic System, a clotting product the company sold to Baxter (BAX). Read more here.
Artivion Announces FDA PMA Approval of PerClot and Transfer of PMA to Baxter
/PRNewswire/ -- Artivion, Inc. (NYSE: AORT), a leading cardiac and vascular surgery company focused on aortic disease, today announced that the U.S. Food and...